Cytomegalovirus infection in the first year of life in human immunodeficiency virus-infected children: Impact on survival and progression of the HIV disease

Medical Science Monitor

Volumn 13, Issue 4, 2007, Pages

  Marín Gabriel, Miguel Ángel ^a   Ramos Amador, José Tomás ^b   González Tomé, Maribel ^a   Rojo Conejo, Pablo ^a   Saavedra Lozano, Jesús ^a   De La Cruz Bértolo, Javier ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Children; Cytomegalovirus; HAART; HIV infection

Indexed keywords

ANTIRETROVIRUS AGENT; GANCICLOVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; PROSPECTIVE STUDY; SURVIVAL; URINE CULTURE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CHILD, PRESCHOOL; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; DISEASE PROGRESSION; FLOW CYTOMETRY; HUMANS; IMMUNE TOLERANCE; PROSPECTIVE STUDIES; SPAIN;

EID: 34147163351     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Reus S, Portilla J, Gimeno A et al: Predoctores de progresión y muerte en pacientes con infección avanzada por el VIH en la era de los tratamientos antirretrovirales de gran actividad. Enferm Infecc Microbiol Clin, 2004; 22(3): 142-49
2. Saillour F, Bernard N, Dequae-Merchadou L et al: Predictive factors of occurrence of cytomegalovirus disease and impact on survival in the Aquitaine cohort in France, 1985 to 1994. J Acquir Immune Defic Syndr Hum Retrovirol, 1998; 17(2): 171-78
3. Chandwani S, Kaul A, Bebenroth D et al: Cytomegalovirus infection in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J, 1996; 15(4): 310-14
4. Sławska H, Czuba B, Mazurek U et al: Intrauterine foetal infection by Cytomegaly Virus - dependence between the CMV presence intensification in amniotic fluid and neonatal well-being. Med Sci Monit, 2004; 10(Suppl.2): 53-57
5. Schooley RT: Cytomegalovirus in the setting of infection with human immunodeficiency virus. Rev Infect Dis, 1990; 12(Suppl.7): S811-19
6. Zaknun D, Zangerle R, Kapelari K et al: Concurrent ganciclovir and foscarnet treatment for cytomegalovirus encephalitis and retinitis in an infant with acquired immunodeficiency syndrome: case report and review. Pediatr Infect Dis J, 1997; 16: 807-11
7. Likitnukul S, Bhattarakosol P, Poovorawan Y: Seroprevalence of cytomegalovyrus infection in children born to HIV-1 infected women. Asian Pac J Allergy Immunol, 2003; 21: 127-30
8. Mussi-Pinhata MM, Yamamoto AY, Figueiredo LT et al: Congenital and perinatal cytomegalovirus infection in infant born to mothers infected with human immunodeficiency virus. J Pediatr, 1998; 132: 285-90
9. Pillay T, Adhikari M, Mokili J et al: Severe, rapidly progressive human immunodeficiency virus type 1 disease in newborns with coinfections. PIDJ, 2001; 20: 404-10
10. Marín Gabriel MA, Fernández Ibieta M, Gonzalez Tomé MI et al: Congenital cytomegalovirus infection in the infants of HIV-infected mothers. An Pediatr, 2005; 62(1): 38-42
11. Kimberlin DW, Lin CY, Sánchez PJ et al: Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr, 2003; 143: 16-25
12. Whitley RJ, Cloud G, Gruber W et al: Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. J Infect Dis, 1997; 175(5): 1080-86
13. Michaels MG, Greenberg DP, Sabo DL, Wald ER: Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatr Infect Dis J, 2003; 22: 504-8
14. Shepp D, Moses J, Kaplan M: Seroepidemiology of cytomegalovirus in patients with advanced HIV disease: influence on disease expression and survival. J Acquir Immune Defic Syndr Hum Retrovirol, 1996 ; 11(5): 460-68
15. Frenkel LD, Gaur S, Tsolia M et al: Cytomegalovirus infection in children with AIDS. Rev Infect Dis. 1990; 12(Suppl.7): S820-26
16. Deayton JR, Sabin CA, Johnson MA et al: Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet, 2004; 363: 2116-21
17. Spector SA, Wong R, Hsia K et al: Plasma cytomegalovirus DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest, 1998; 101(2): 497-502
18. Chevret S, Scieux C, Garrait V et al: Usefulness of the cytomegalovirus antigenemia assay for predicting the occurrence of CMV disease and death in patients with AIDS. Clin Infect Dis, 1999; 28(4): 758-63
19. No authors listed. CMV load acts as predictor of HIV progression. Aids Alert, 1997; 12: 139-40
20. Spector SA, Hsia K, Crager M et al: Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol, 1999; 73(8): 7027-30
21. Sinicco A, Raiteri R, Sciandra M et al: The influence of cytomegalovirus on the natural history of HIV infection: evidence of rapid course of HIV infection in HIV-positive patients infected with cytomegalovirus. Scand J Infect Dis, 1997; 29(6): 543-49
22. Kovacs A, Schluchter M, Easley K et al: Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med, 1999; 341(2): 77-84
23. Kitchen B, Engler H, Gill VJ et al: Cytomegalovirus infection in children with human immunodeficiency virus infection. Pediatr Infect Dis J, 1997; 16(4): 358-63
24. Doyle M, Atkins J, Rivera-Matos I: Congenital cytomegalovirus infection in infants infected with human immunodeficiency virus type 1. Pediatr Infect Dis J, 1996; 15(12): 1102-6
25. Robain M, Boufassa F, Hubert JB et al: Is cytomegalovirus infection a co-factor in HIV-1 disease progression? Epidemiol Infect, 2000; 125(2): 415-20
26. Williams AJ, Duong T, McNally LM et al: Pneumocystis carinii pneumonia and cytomegalovirus infection in children with vertically acquired HIV infection. AIDS, 2001; 15: 335-39
27. De Rossi A: Primary HIV infection in infants: impact of highly active antiretroviral therapy on the natural course. J Biol Regul Homeost Agents, 2002; 16(1): 53-57
28. Walker AS, Doerholt K, Sharland M, Gibb DM; Collaborative HIV Paediatric Study Steering Committee. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS, 2004; 18(14): 1915-24
29. Sanchez JM, Ramos Amador JT, Fernandez de Miguel S et al: Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J, 2003; 22(10): 863-67
30. Jaspan HB, Garry RF: Preventing neonatal HIV: a review. Curr HIV Res, 2003; 1(3): 321-27
31. Mofenson LM: Advances in the prevention of vertical transmission of human immunodeficiency virus. Semin Pediatr Infect Dis, 2003; 14(4): 295-308